吉非替尼治疗化疗后进展晚期非小细胞肺癌临床观察.docVIP

吉非替尼治疗化疗后进展晚期非小细胞肺癌临床观察 　　摘要：目的 分析吉非替尼对化疗后进展的晚期非小细胞肺癌患者的临床治疗效果。方法 以我院2008年1月~2010年12月应用常规治疗的29例化疗后进展的晚期非小细胞肺癌患者为常规组，以我院同期加用吉非替尼治疗的29例患者为吉非替尼组，比较两组患者治疗后疾病控制率、中位生存时间及不良反应发生情况。结果 吉非替尼组治疗后疾病控制率显著高于常规组，中位生存时间显著长于常规组，不良反应发生率显著低于常规组，两组各项数据经比较差异具有统计学意义，（P0.05）。结论 应用吉非替尼治疗化疗后进展的晚期非小细胞肺癌，患者治疗有效率显著提高，生存时间有所延长，安全可靠，值得临床推广应用。 　　关键词：吉非替尼；化疗；晚期非小细胞肺癌 　　To Observe the Curative Effect of Gefitinib for Progressed after Chemotherapy NSCLC 　　ZHOU Wen-wei,LI Chun-xia,CHEN Jian-hua,WANG Wei,YAO Ding-quan,YI Hui-huang 　　(The Tumor Hospital of Hunan Province/Affiliated Tumor Hospital of Xiangya Medical College of Central South University,Changsha 410013,Hunan,China) 　　Abstract：ObjectiveTo analyze the progress of patients with advanced non-small cell lung cancer after chemotherapy in the clinical treatment effect. MethodsFrom January 2008 to December 2010 between the application of conventional treatment of 29 cases progress of patients with advanced non-small cell lung cancer after chemotherapy for conventional group, the same period in our hospital and the treatment with the treatment for the treatment of 29 cases of patients group, compared two groups of patients after the disease control rates, the median survival time and adverse reactions occur. ResultsThe treatment group after the disease control rates significantly higher than that of conventional group, the median survival time was significantly longer than the normal group, incidence of adverse reactions was significantly lower than normal group, two groups of data by comparing differences statistically significant, (P 0.05). ConclusionGefitinib treatment progress of advanced non-small cell lung cancer after chemotherapy, effectively improve patient treatment, survival time was extended, safe and reliable, worthy of clinical popularization and application. 　　Key words：Gefitinib;Chemotherapy;Advanced non-small cell lung cancer 　　 　　非小细胞肺癌是最常见的恶性肿瘤之一，发病率与死亡率极高，大多数患者确诊时已属于中晚期，化疗是该病主要治疗手段，但往往难以达到根治的目的。化疗后进展的晚期非小细胞肺癌患者多应用吉非替